ST
Samsara Therapeutics develops therapeutics for age-related neurodegenerative diseases by focusing on the activation of autophagy pathways. The company utilizes an in-house phenotypic screening platform with patient-derived iPSCs to identify small molecule autophagy activators. This approach aims to delay disease progression in conditions such as ALS, Parkinson's Disease, and CMT.
Updated 3 months ago
Funding
$38.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Samsara Therapeutics develops therapeutics for age-related neurodegenerative diseases by focusing on the activation of autophagy pathways. The company utilizes an in-house phenotypic screening platform with patient-derived iPSCs to identify small molecule autophagy activators. This approach aims to delay disease progression in conditions such as ALS, Parkinson's Disease, and CMT.